These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 27480131

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
    Burke CA, Dekker E, Lynch P, Samadder NJ, Balaguer F, Hüneburg R, Burn J, Castells A, Gallinger S, Lim R, Stoffel EM, Gupta S, Henderson A, Kallenberg FG, Kanth P, Roos VH, Ginsberg GG, Sinicrope FA, Strassburg CP, Van Cutsem E, Church J, Lalloo F, Willingham FF, Wise PE, Grady WM, Ford M, Weiss JM, Gryfe R, Rustgi AK, Syngal S, Cohen A.
    N Engl J Med; 2020 Sep 10; 383(11):1028-1039. PubMed ID: 32905675
    [Abstract] [Full Text] [Related]

  • 4. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW.
    JAMA Oncol; 2018 May 01; 4(5):671-677. PubMed ID: 29423501
    [Abstract] [Full Text] [Related]

  • 5. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
    Giardiello FM, Casero RA, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW.
    Gastroenterology; 2004 Feb 01; 126(2):425-31. PubMed ID: 14762779
    [Abstract] [Full Text] [Related]

  • 6. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
    Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK.
    Br J Surg; 1993 Dec 01; 80(12):1618-9. PubMed ID: 8298943
    [Abstract] [Full Text] [Related]

  • 7. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW.
    Nutr Cancer; 2008 Dec 01; 60 Suppl 1():30-5. PubMed ID: 19003578
    [Abstract] [Full Text] [Related]

  • 8. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
    Keller JJ, Offerhaus GJ, Polak M, Goodman SN, Zahurak ML, Hylind LM, Hamilton SR, Giardiello FM.
    Gut; 1999 Dec 01; 45(6):822-8. PubMed ID: 10562579
    [Abstract] [Full Text] [Related]

  • 9. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, Bommi PV, Taggart MW, Thirumurthi S, Lynch PM, Reyes-Uribe L, Scheet PA, Sinha KM, Vilar E.
    Cancer Prev Res (Phila); 2021 Sep 01; 14(9):851-862. PubMed ID: 34266857
    [Abstract] [Full Text] [Related]

  • 10. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
    Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW.
    Gastroenterology; 2010 Sep 01; 139(3):797-805, 805.e1. PubMed ID: 20538001
    [Abstract] [Full Text] [Related]

  • 11. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H, Mutoh M, Sato Y, Doyama H, Tajika M, Tanaka S, Horimatsu T, Takeuchi Y, Kashida H, Tashiro J, Ezoe Y, Nakajima T, Ikematsu H, Hori S, Suzuki S, Otani T, Takayama T, Ohda Y, Mure K, Wakabayashi K, Sakai T.
    Lancet Gastroenterol Hepatol; 2021 Jun 01; 6(6):474-481. PubMed ID: 33812492
    [Abstract] [Full Text] [Related]

  • 12. Chemoprevention in familial adenomatous polyposis: past, present and future.
    Kemp Bohan PM, Mankaney G, Vreeland TJ, Chick RC, Hale DF, Cindass JL, Hickerson AT, Ensley DC, Sohn V, Clifton GT, Peoples GE, Burke CA.
    Fam Cancer; 2021 Jan 01; 20(1):23-33. PubMed ID: 32507936
    [Abstract] [Full Text] [Related]

  • 13. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
    Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E.
    Gut; 2016 Feb 01; 65(2):286-95. PubMed ID: 25792707
    [Abstract] [Full Text] [Related]

  • 14. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis.
    Seow-Choen F, Vijayan V, Keng V.
    Br J Surg; 1996 Dec 01; 83(12):1763-6. PubMed ID: 9038563
    [Abstract] [Full Text] [Related]

  • 15. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
    Hisamuddin IM, Wehbi MA, Chao A, Wyre HW, Hylind LM, Giardiello FM, Yang VW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8357-62. PubMed ID: 15623613
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ, Foster N, McMurray RP, Burke CA, Stoffel E, Kanth P, Das R, Cruz-Correa M, Vilar E, Mankaney G, Buttar N, Thirumurthi S, Turgeon DK, Sossenheimer M, Westover M, Richmond E, Umar A, Della'Zanna G, Rodriguez LM, Szabo E, Zahrieh D, Limburg PJ.
    Gut; 2023 Feb 15; 72(2):256-263. PubMed ID: 35636921
    [Abstract] [Full Text] [Related]

  • 17. Chemoprevention of familial adenomatous polyposis.
    Lynch PM.
    Fam Cancer; 2016 Jul 15; 15(3):467-75. PubMed ID: 27083160
    [Abstract] [Full Text] [Related]

  • 18. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM, Rajendran P, Dashwood WM, Yavuz OF, Kapoor S, Gustafson TA, Savage MI, Brown PH, Sei S, Mohammed A, Vilar E, Dashwood RH.
    Cancer Prev Res (Phila); 2021 Mar 15; 14(3):325-336. PubMed ID: 33277315
    [Abstract] [Full Text] [Related]

  • 19. Primary chemoprevention of familial adenomatous polyposis with sulindac.
    Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR.
    N Engl J Med; 2002 Apr 04; 346(14):1054-9. PubMed ID: 11932472
    [Abstract] [Full Text] [Related]

  • 20. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Familial Adenomatous Polyposis Study Group.
    Cancer Epidemiol Biomarkers Prev; 2004 Jun 04; 13(6):920-7. PubMed ID: 15184247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.